Nevertheless, for patients with NPM-ALK-positive subtypes, two targeted therapeutic approaches are available: one involves the use of an ALK inhibitor, while the other targets CD30, a surface marker molecule that is highly expressed on anaplastic large-cell lymphoma cells. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.